Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 9.65B +0.1% |
| Revenue (ttm) | 874.09M -7.4% |
| Net Income | -565.17M |
| EPS | -3.46 |
| Shares Out | 166.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,671,092 |
| Open | 58.36 |
| Previous Close | 58.13 |
| Day's Range | 57.78 - 58.96 |
| 52-Week Range | 50.01 - 86.74 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 87.77 (+51.09%) |
| Earnings Date | Oct 28, 2026 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for IONS stock is "Buy." The 12-month stock price target is $87.77, which is an increase of 51.09% from the latest price.
News
Citi sees limited immediate downside for Ionis after pelacarsen failure
After Ionis’ (IONS) partner Novartis (NVS) disclosed that the pelacarsen Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint of cardiovascular risk reduction, Citi analyst Eric Joseph antic...
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing ...
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes tria...
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Ionis Pharmaceuticals Transcript: FDA announcement
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. Approval was based on robust clinical data showing significant motor function benefit and favorable safety. Launch efforts focus on rapid patient access, payer coverage, and global expansion.
Ionis Pharmaceuticals Press release: FDA announcement
Ionis Pharmaceuticals issued a press release on September 4, 2026, disclosing material business information to investors.
Ionis Pharmaceuticals Slides: FDA announcement
Ionis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital
BMO Capital analyst David Lebowitz raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $61 from $60 and keeps a Market Perform rating on the shares. The FDA approved…
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment o...
US FDA approves Ionis Pharma's therapy to treat rare brain disorder
The U.S. FDA on Thursday approved Ionis Pharmaceuticals' therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorde...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Well...
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
After Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN) presented full results of the Cardio-TTRansform trial at the ESC Congress 2026 in Munich, Jefferies said the data came in “mostly as expected.”...
Ionis announces new data in sHTG to be presented at ESC Congress 2026
Ionis Pharmaceuticals (IONS) announced that new data in the management of severe hypertriglyceridemia, sHTG, will be presented at the European Society of Cardiology, ESC, Congress 2026, taking place A...
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European So...
BMO Capital starts Ionis at Market Perform pending better visibility
BMO Capital initiated coverage of Ionis Pharmaceuticals (IONS) with a Market Perform rating and $60 price target The company now markets two wholly owned products, Tryngolza and Dawnzera, with a…
Ionis Pharmaceuticals initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Ionis Pharmaceuticals (IONS) with a Market Perform rating and $60 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considere...
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Ionis Pharmaceuticals price target raised to $76 from $72 at JPMorgan
JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $76 from $72 and keeps an Overweight rating on the shares. The firm updated the company’s model after meeting…
Ionis Pharmaceuticals price target raised to $93 from $90 at BofA
BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $93 from $90 and keeps a Buy rating on the shares. The firm continues to see a favorable risk/reward…
Ionis Pharmaceuticals price target lowered to $115 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $115 from $125 and keeps a Buy rating on the shares. The firm views the company’s Q2 report…
Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $66 and keeps a Neutral rating on the shares after its better than expected Q2 results.
Ionis Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 and H1 revenues grew significantly year-over-year, driven by strong launches of TRYNGOLZA and DAWNZERA. TRYNGOLZA's sHTG launch is progressing well, with expanding payer coverage and robust demand, while DAWNZERA continues to gain share in HAE prophylaxis.
Ionis Pharmaceuticals Earnings release: Q2 2026
Ionis Pharmaceuticals released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Ionis Pharmaceuticals Slides: Q2 2026
Ionis Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.